Business Context and Reporting Period
This Form 8-K is filed by AmerisourceBergen Corporation (now known as Cencora, Inc.) for the reporting date of March 21, 2006. The filing reports a material corporate event involving the company's Canadian subsidiary.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics for the reporting period. The only specific financial figure disclosed relates to a transaction:
- Acquisition Cost: Approximately US$18 million for the purchase of assets.
Material Changes
The primary material change reported is the completion of an acquisition:
- Acquirer: AmerisourceBergen Canada Corporation (a wholly owned subsidiary).
- Target: Substantially all assets of privately held Asenda Pharmaceutical Supplies Ltd. and a related entity.
- Transaction Date: Completed on March 21, 2006.
Guidance, Outlook, and Risks
The filing text does not provide updated financial guidance, management commentary on future outlook, specific risk factors, or contingencies related to this transaction. The document serves solely to announce the completion of the asset purchase.
Investor Verification Checklist
- Verify the strategic rationale for acquiring Asenda Pharmaceutical Supplies Ltd. in the Canadian market.
- Confirm the integration timeline and expected impact on the company's North American pharmaceutical distribution network.
- Review the full text of the news release (Exhibit 99.1) for details on the target's revenue or market share, which are not included in the 8-K summary.
- Check subsequent filings for any goodwill impairment or integration costs associated with the US$18 million investment.